Cited 89 times in
Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 김영태 | - |
dc.contributor.author | 김재욱 | - |
dc.contributor.author | 김재훈 | - |
dc.contributor.author | 남은지 | - |
dc.contributor.author | 윤보성 | - |
dc.contributor.author | 조혜진 | - |
dc.date.accessioned | 2014-12-21T16:38:27Z | - |
dc.date.available | 2014-12-21T16:38:27Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/96070 | - |
dc.description.abstract | OBJECTIVE: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. METHODS: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). RESULTS: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P=0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P=0.04). CONCLUSION: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 199~204 | - |
dc.relation.isPartOf | GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anemia/etiology | - |
dc.subject.MESH | Anemia/prevention & control* | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Cisplatin/adverse effects | - |
dc.subject.MESH | Cisplatin/therapeutic use | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Ferric Compounds/therapeutic use* | - |
dc.subject.MESH | Ferric Oxide, Saccharated | - |
dc.subject.MESH | Glucaric Acid | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Uterine Cervical Neoplasms/blood* | - |
dc.subject.MESH | Uterine Cervical Neoplasms/drug therapy | - |
dc.subject.MESH | Uterine Cervical Neoplasms/radiotherapy | - |
dc.subject.MESH | Uterine Cervical Neoplasms/therapy* | - |
dc.title | Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Jae Wook Kim | - |
dc.contributor.googleauthor | Jae Hoon Kim | - |
dc.contributor.googleauthor | Sung Hoon Kim | - |
dc.contributor.googleauthor | Eun Ji Nahm | - |
dc.contributor.googleauthor | Hye Jin Cho | - |
dc.contributor.googleauthor | Bo Sung Yoon | - |
dc.identifier.doi | 10.1016/j.ygyno.2006.11.014 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A00866 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A00876 | - |
dc.contributor.localId | A01262 | - |
dc.contributor.localId | A02554 | - |
dc.contributor.localId | A03939 | - |
dc.relation.journalcode | J00956 | - |
dc.identifier.eissn | 1095-6859 | - |
dc.identifier.pmid | 17234260 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0090825806009292 | - |
dc.contributor.alternativeName | Kim, Sang Wun | - |
dc.contributor.alternativeName | Kim, Sung Hoon | - |
dc.contributor.alternativeName | Kim, Young Tae | - |
dc.contributor.alternativeName | Kim, Jae Wook | - |
dc.contributor.alternativeName | Kim, Jae Hoon | - |
dc.contributor.alternativeName | Nam, Eun Ji | - |
dc.contributor.alternativeName | Yoon, Bo Sung | - |
dc.contributor.alternativeName | Cho, Hye Jin | - |
dc.contributor.affiliatedAuthor | Kim, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Jae Wook | - |
dc.contributor.affiliatedAuthor | Kim, Sang Wun | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Kim, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Nam, Eun Ji | - |
dc.contributor.affiliatedAuthor | Yoon, Bo Sung | - |
dc.contributor.affiliatedAuthor | Cho, Hye Jin | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 105 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 199 | - |
dc.citation.endPage | 204 | - |
dc.identifier.bibliographicCitation | GYNECOLOGIC ONCOLOGY, Vol.105(1) : 199-204, 2007 | - |
dc.identifier.rimsid | 35410 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.